With regard to M/A, I think it would be in our best interest if we were to court a company that is about to owe us a huge sum of money resulting from a positive outcome in  EDoT.

There must be a company out there somewhere whose technology nearly totally infringes our patient portfolio. In as much we would have a natural symbioses and the price we would have to pay to merge would be substantially reduced by the amount of the settlement due.

This way we could either eliminate money to be borrowed or at least, reduce the figure.

GLTA